483
Hangzhou ApexTide Biomedical Technology Co., Ltd.Hangzhou ApexTide Biomedical Technology Co., Ltd. – FDA 483, Nov 1, 2024
Record Details
An FDA inspection of Hangzhou ApexTide Biomedical Technology Co., Ltd. in Hangzhou, China, revealed significant deficiencies in the manufacturing and quality control of Active Pharmaceutical Ingredients (API). The firm failed to complete process validation, adequately qualify manufacturing areas and equipment, and ensure proper testing of starting materials and water used in production. These issues raise concerns about the quality, purity, and stability of API shipped to the US market.
- Inspection date
- November 1, 2024
- Product type
- drugs
View Company Profile
ID · dfe41cbb-6066-4438-878c-f19ec1361dc5
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.